APLIF (Appili Therapeutics) LT-Debt-to-Total-Asset: 1.35 (As of Dec. 2025)


What is Appili Therapeutics LT-Debt-to-Total-Asset?

Appili Therapeutics APLIF LT-Debt-to-Total-Asset is 1.35 as of Dec. 2025. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Appili Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 1.35.

Appili Therapeutics's long-term debt to total assets ratio increased from Dec. 2024 (0.39) to Dec. 2025 (1.35). It may suggest that Appili Therapeutics is progressively becoming more dependent on debt to grow their business.

Appili Therapeutics  (OTCPK:APLIF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Appili Therapeutics LT-Debt-to-Total-Asset Related Terms

Appili Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Appili Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Appili Therapeutics LT-Debt-to-Total-Asset Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.05 0.59 2.41 0.59 0.24

Appili Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.24 0.37 0.81 1.35

Appili Therapeutics LT-Debt-to-Total-Asset Calculation

Appili Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (A: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2025 )/Total Assets (A: Mar. 2025 )
=0.513/2.113
=0.24

Appili Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=0.534/0.397
=1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 1.35 mean?
Appili Therapeutics (APLIF) has a LT-Debt-to-Total-Asset of 1.35 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Appili Therapeutics and its competitors.
Is Appili Therapeutics' LT-Debt-to-Total-Asset too high?
Appili Therapeutics' current LT-Debt-to-Total-Asset is 1.35.
How does Appili Therapeutics' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Appili Therapeutics' LT-Debt-to-Total-Asset of 1.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Appili Therapeutics and its competitors. Appili Therapeutics's current LT-Debt-to-Total-Asset is 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (APLIF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 43.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 1.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Appili Therapeutics (APLIF), the current LT-Debt-to-Total-Asset is 1.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Appili Therapeutics Business Description

Other Exchanges APLI:Canada
Address 1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.